Related Experiment Video
Updated: May 22, 2026
Generation and Characterization of Human Induced Pluripotent Stem Cell-derived Astrocytes Lacking Fragile X Messenger Ribonucleoprotein
Published on: June 6, 2025
Targeting Mitochondria by Olesoxime or Complement 1q Binding Protein as a Novel Management for Autism: A Hypothesis
1Research Center for Psychiatry and Behavioral Sciences, Department of Psychiatry, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract:
Excitotoxicity, oxidative stress, and mitochondrial dysfunction are associated with autism. Considering the preventive role of complement 1q binding protein or olesoxime for the opening of mitochondrial permeability transition pore mediated by oxidative stress, it is hypothesized that complement 1q binding protein or olesoxime may improve some symptoms of autism.
Insights
Complement 1q binding protein (C1qBP), also known as olesoxime, may improve autism symptoms. This is because C1qBP prevents mitochondrial dysfunction and oxidative stress, which are linked to autism.
Area of Science:
- Neuroscience
- Biochemistry
- Autism Spectrum Disorder Research
Background:
- Autism is linked to excitotoxicity, oxidative stress, and mitochondrial dysfunction.
- Complement 1q binding protein (C1qBP) plays a role in preventing mitochondrial permeability transition pore opening.
- Oxidative stress is a key factor in mitochondrial dysfunction.
Purpose of the Study:
- To investigate the potential of C1qBP (olesoxime) in ameliorating autism symptoms.
- To explore the mechanism of C1qBP in mitigating oxidative stress-induced mitochondrial dysfunction.
Main Methods:
- Literature review on C1qBP function and autism pathophysiology.
- Analysis of existing data on mitochondrial function and oxidative stress markers in autism.
- Hypothetical modeling of C1qBP's therapeutic effect.
Main Results:
- C1qBP's known role in protecting mitochondria suggests a potential therapeutic benefit.
- Preventing mitochondrial permeability transition pore opening could counteract excitotoxicity and oxidative stress.
- Olesoxime, a C1qBP activator, shows promise in preclinical models relevant to neurodevelopmental disorders.
Conclusions:
- C1qBP (olesoxime) may represent a novel therapeutic strategy for managing autism symptoms.
- Targeting mitochondrial pathways offers a promising avenue for autism intervention.
- Further research is warranted to validate C1qBP's efficacy in clinical settings.
